CVRX INC (CVRX)

Company Profile

CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 160 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing neuromodulation solutions for patients with cardiovascular diseases. The firm's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.

Company Info

CVRX INC

9201 West Broadway Avenue, Suite 650

Minneapolis MINNESOTA

P: 17634162850

CEO: Nadim Yared

Employees: 160

Website: https://www.cvrx.com/